AGMT Austrian CLL (chronic lymphocytic leukemia) Registry
Short title: AGMT_CLL-Reg
Title: AGMT Austrian CLL (chronic lymphocytic leukemia) Registry
Start: März 2022
Coordinating Investigator: Univ. Prof. Dr. Richard Greil
NIS Number: NIS024234
Number of patients: 500 (planned)
Sponsor: AGMT gemeinnützige GmbH
This registry is designed as multicenter observational cohort of patients with CLL. Patient medical, testing and treatment information will be obtained through extraction of data from existing patient medical charts. Longitudinal follow-up data, including survival and tumor progression, will also be extracted from patient medical charts. This patient follow-up data will be obtained until patient death or loss to follow-up.
Only routine data, which has already been recorded in the patient’s medical chart, is transferred to the electronic Case Report Forms.
The CLL registry will be accompanied by an optional biobanking program.
The goal of this registry is to build a disease-specific registry aimed at assessing the therapeutic landscape of patients with CLL in Austria. It will be set up to collect real-world experience in the management of patients with this disease. This registry will collect data at various sites in Austria. The aim is to gain valuable insights on both efficacy and toxicity, as well as the sequence of use of various treatments in a routine clinical setting.
The broad range of data collected within the scope of the AGMT CLL registry provides the possibility to identify and address further objectives.
Physicians will select appropriate patients for enrollment. Appropriate patients are expected to:
- Age >= 18 years
- Diagnosis of CLL
- Be willing to provide informed consent
Due to the non-interventional design of this program there are no specific in- or exclusion criteria.